[Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells]

Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 May;47(3):316-20, 336.
[Article in Chinese]

Abstract

Objective: To assess the sensitisation effects of DDR inhibitors combined with conventional chemotherapeutics agents (cisplatin et al) in a drug-resistant ovarian cancer cell line(OVCAR-8).

Methods: Inhibitors of DDR regulators with cisplatin were applied to challenge OVCAR-8, and evaluated the DNA damage response (DDR) and cytotoxic effects of different combination of chemicals. Inhibition of proliferation to OVCAR-8 of different drugs was evaluated by MTT assay. The activation of phosphorylation of histone family 2A variant (yH2AX) and p53 binding protein 1 (53BP1) in OVCAR-8 were evaluated by immunofluorescence to observe their ability of recruitment and forming foci at DNA damage site.

Results: We observed that combined treatment of ataxia-telangiectasia mutated (ATM)/ATM and Rad 3-related (ATR) inhibitor and cisplatin can suppress the activation of damage repair mechanisms and weakened the proliferative activity of OVCAR-8 cells (P<0. 01) ; ATR pathway was suppressed and the signal of γH2AX weakened and cell survival rate significantly reduced when combination therapy of HU and Wortmannin (P < 0.05); poly ADP-ribose polymerase (PARP) inhibitor could not enhance chemosensitivity in OVCAR-8 cells when combined with cisplatin (P > 0.05).

Conclusion: We substantiated that appropriate inhibitors of DNA damage response may have a potential to improve the anti-tumor effect of conventional chemotherapy drugs and prevent drug resistances.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Ataxia Telangiectasia Mutated Proteins / antagonists & inhibitors
  • Cell Line, Tumor / drug effects
  • Cisplatin / pharmacology*
  • DNA Damage*
  • Drug Resistance, Neoplasm
  • Female
  • Histones / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Ovarian Neoplasms / pathology*
  • Phosphorylation
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
  • Tumor Suppressor p53-Binding Protein 1

Substances

  • Antineoplastic Agents
  • Histones
  • Intracellular Signaling Peptides and Proteins
  • Poly(ADP-ribose) Polymerase Inhibitors
  • TP53BP1 protein, human
  • Tumor Suppressor p53-Binding Protein 1
  • Ataxia Telangiectasia Mutated Proteins
  • Cisplatin